We sought to determine if online aligned education for clinicians and patients could improve understanding and use of GLP-1 RAs for T2D. For clinicians, a live-streamed virtual symposium was held as part of the 2021 Metabolic and Endocrine Disease Summit (MEDS) summer (July) and fall (October) meetings, followed by an enduring available in August, 2021. Pre/post questions were used to assess changes in knowledge, confidence and practice. For patients, the online text, integrated visuals and patient video activity, which launched in June 2021, used a pre/post knowledge question and post-activity intent to change and confidence questions to assess impact. Absolute improvements were calculated for all questions, data collected through November 1, 2021. Clinician Activity Learners: 581 (Summer) and 364 (Fall) . Demographics: 47%-56% were nurse practitioners, 22% physician assistants, and 9%-12% physicians. Knowledge changes: 13%-16% increase in recognizing GLP-1 RAs with CV benefits/indications, 6%-7% increase in identifying weight loss as a benefit of GLP-1 RAs, 12%-23% increase in selecting patient education to help mitigate side effects. After the education, 80%-86% reported confidence in starting a patient with CVD/obesity on a GLP-1 RA. Enduring Learners: 1,662 clinicians (as of November 1, 2021) . Patient Activity: 11,029 learners have participated in the patient/caregiver activity, “Understanding the Use of GLP-1 Receptor Agonists for Type 2 Diabetes.” Knowledge changes: 22% increase in recognizing how GLP-1 RAs work (39% pre to 61% post) . Intent-to-act: 70% plan to talk to their HCP about if taking a GLP-1 RA can help manage their T2D better. Confidence changes: 78% reported increased confidence in talking to my HCP about GLP-1 RAs for T2D. These outcomes are a strong indicator that aligned clinician and patient activities are successful at improving both clinicians’ and patients’ understanding and use of GLP-1 RAs for T2D.
A.Larkin: None. A.Le: None.
Independent Educational Grant from Novo Nordisk.